ID   MAPK2_HUMAN             Reviewed;         400 AA.
AC   P49137; Q5SY30; Q5SY41; Q8IYD6;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   15-MAR-2017, entry version 180.
DE   RecName: Full=MAP kinase-activated protein kinase 2;
DE            Short=MAPK-activated protein kinase 2;
DE            Short=MAPKAP kinase 2;
DE            Short=MAPKAP-K2;
DE            Short=MAPKAPK-2;
DE            Short=MK-2;
DE            Short=MK2;
DE            EC=2.7.11.1;
GN   Name=MAPKAPK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=8179591; DOI=10.1006/bbrc.1994.1566;
RA   Zu Y.-L., Wu F., Gilchrist A., Ai Y., Labadia M.E., Huang C.K.;
RT   "The primary structure of a human MAP kinase activated protein kinase
RT   2.";
RL   Biochem. Biophys. Res. Commun. 200:1118-1124(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 5-400 (ISOFORM 1), AND FUNCTION.
RX   PubMed=8280084; DOI=10.1042/bj2960843;
RA   Stokoe D., Caudwell B., Cohen P.T.W., Cohen P.;
RT   "The substrate specificity and structure of mitogen-activated protein
RT   (MAP) kinase-activated protein kinase-2.";
RL   Biochem. J. 296:843-849(1993).
RN   [6]
RP   FUNCTION IN PHOSPHORYLATION OF HSPB1.
RX   PubMed=8093612;
RA   Jakob U., Gaestel M., Engel K., Buchner J.;
RT   "Small heat shock proteins are molecular chaperones.";
RL   J. Biol. Chem. 268:1517-1520(1993).
RN   [7]
RP   PHOSPHORYLATION AT SER-9; THR-25; THR-222; SER-272 AND THR-334, AND
RP   MUTAGENESIS OF ASP-207; THR-222; SER-272 AND THR-334.
RX   PubMed=8846784;
RA   Ben-Levy R., Leighton I.A., Doza Y.N., Attwood P., Morrice N.,
RA   Marshall C.J., Cohen P.;
RT   "Identification of novel phosphorylation sites required for activation
RT   of MAPKAP kinase-2.";
RL   EMBO J. 14:5920-5930(1995).
RN   [8]
RP   CATALYTIC ACTIVITY, AND FUNCTION IN PHOSPHORYLATION OF HSPB1.
RX   PubMed=8774846; DOI=10.1016/0014-5793(96)00816-2;
RA   Clifton A.D., Young P.R., Cohen P.;
RT   "A comparison of the substrate specificity of MAPKAP kinase-2 and
RT   MAPKAP kinase-3 and their activation by cytokines and cellular
RT   stress.";
RL   FEBS Lett. 392:209-214(1996).
RN   [9]
RP   FUNCTION IN PHOSPHORYLATION OF HSPB1.
RX   PubMed=10383393; DOI=10.1074/jbc.274.27.18947;
RA   Rogalla T., Ehrnsperger M., Preville X., Kotlyarov A., Lutsch G.,
RA   Ducasse C., Paul C., Wieske M., Arrigo A.P., Buchner J., Gaestel M.;
RT   "Regulation of Hsp27 oligomerization, chaperone function, and
RT   protective activity against oxidative stress/tumor necrosis factor
RT   alpha by phosphorylation.";
RL   J. Biol. Chem. 274:18947-18956(1999).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF HNRNPA0.
RX   PubMed=12456657; DOI=10.1093/emboj/cdf639;
RA   Rousseau S., Morrice N., Peggie M., Campbell D.G., Gaestel M.,
RA   Cohen P.;
RT   "Inhibition of SAPK2a/p38 prevents hnRNP A0 phosphorylation by MAPKAP-
RT   K2 and its interaction with cytokine mRNAs.";
RL   EMBO J. 21:6505-6514(2002).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF LOX5.
RX   PubMed=11844797; DOI=10.1074/jbc.M111945200;
RA   Werz O., Szellas D., Steinhilber D., Radmark O.;
RT   "Arachidonic acid promotes phosphorylation of 5-lipoxygenase at Ser-
RT   271 by MAPK-activated protein kinase 2 (MK2).";
RL   J. Biol. Chem. 277:14793-14800(2002).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF PABPC1.
RX   PubMed=12565831; DOI=10.1016/S0006-291X(03)00015-9;
RA   Bollig F., Winzen R., Gaestel M., Kostka S., Resch K., Holtmann H.;
RT   "Affinity purification of ARE-binding proteins identifies polyA-
RT   binding protein 1 as a potential substrate in MK2-induced mRNA
RT   stabilization.";
RL   Biochem. Biophys. Res. Commun. 301:665-670(2003).
RN   [13]
RP   FUNCTION.
RX   PubMed=14499342; DOI=10.1016/S0898-6568(03)00074-3;
RA   Coxon P.Y., Rane M.J., Uriarte S., Powell D.W., Singh S., Butt W.,
RA   Chen Q., McLeish K.R.;
RT   "MAPK-activated protein kinase-2 participates in p38 MAPK-dependent
RT   and ERK-dependent functions in human neutrophils.";
RL   Cell. Signal. 15:993-1001(2003).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF ELAVL1, AND MUTAGENESIS OF LYS-93;
RP   THR-222 AND THR-334.
RX   PubMed=14517288; DOI=10.1128/MCB.23.20.7177-7188.2003;
RA   Tran H., Maurer F., Nagamine Y.;
RT   "Stabilization of urokinase and urokinase receptor mRNAs by HuR is
RT   linked to its cytoplasmic accumulation induced by activated mitogen-
RT   activated protein kinase-activated protein kinase 2.";
RL   Mol. Cell. Biol. 23:7177-7188(2003).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF ZFP36, AND MUTAGENESIS OF THR-222 AND
RP   THR-334.
RX   PubMed=15014438; DOI=10.1038/sj.emboj.7600163;
RA   Stoecklin G., Stubbs T., Kedersha N., Wax S., Rigby W.F.,
RA   Blackwell T.K., Anderson P.;
RT   "MK2-induced tristetraprolin:14-3-3 complexes prevent stress granule
RT   association and ARE-mRNA decay.";
RL   EMBO J. 23:1313-1324(2004).
RN   [16]
RP   INTERACTION WITH PHC2.
RX   PubMed=15094067; DOI=10.1016/S0014-5793(04)00351-5;
RA   Yannoni Y.M., Gaestel M., Lin L.L.;
RT   "P66(ShcA) interacts with MAPKAP kinase 2 and regulates its
RT   activity.";
RL   FEBS Lett. 564:205-211(2004).
RN   [17]
RP   FUNCTION IN PHOSPHORYLATION OF CDC25B AND CDC25C.
RX   PubMed=15629715; DOI=10.1016/j.molcel.2004.11.021;
RA   Manke I.A., Nguyen A., Lim D., Stewart M.Q., Elia A.E., Yaffe M.B.;
RT   "MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the
RT   G2/M transition and S phase progression in response to UV
RT   irradiation.";
RL   Mol. Cell 17:37-48(2005).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF LIMK1.
RX   PubMed=16456544; DOI=10.1038/sj.emboj.7600973;
RA   Kobayashi M., Nishita M., Mishima T., Ohashi K., Mizuno K.;
RT   "MAPKAPK-2-mediated LIM-kinase activation is critical for VEGF-induced
RT   actin remodeling and cell migration.";
RL   EMBO J. 25:713-726(2006).
RN   [19]
RP   FUNCTION IN PHOSPHORYLATION OF HSF1, AND INTERACTION WITH HSF1.
RX   PubMed=16278218; DOI=10.1074/jbc.M505822200;
RA   Wang X., Khaleque M.A., Zhao M.J., Zhong R., Gaestel M.,
RA   Calderwood S.K.;
RT   "Phosphorylation of HSF1 by MAPK-activated protein kinase 2 on serine
RT   121, inhibits transcriptional activity and promotes HSP90 binding.";
RL   J. Biol. Chem. 281:782-791(2006).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF LSP1.
RX   PubMed=17481585; DOI=10.1016/j.bbrc.2007.04.104;
RA   Wu Y., Zhan L., Ai Y., Hannigan M., Gaestel M., Huang C.-K.,
RA   Madri J.A.;
RT   "MAPKAPK2-mediated LSP1 phosphorylation and FMLP-induced neutrophil
RT   polarization.";
RL   Biochem. Biophys. Res. Commun. 358:170-175(2007).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF TAB3.
RX   PubMed=18021073; DOI=10.1042/BJ20071149;
RA   Mendoza H., Campbell D.G., Burness K., Hastie J., Ronkina N.,
RA   Shim J.H., Arthur J.S., Davis R.J., Gaestel M., Johnson G.L.,
RA   Ghosh S., Cohen P.;
RT   "Roles for TAB1 in regulating the IL-1-dependent phosphorylation of
RT   the TAB3 regulatory subunit and activity of the TAK1 complex.";
RL   Biochem. J. 409:711-722(2008).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF HNRNPA0 AND PARN, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=20932473; DOI=10.1016/j.molcel.2010.09.018;
RA   Reinhardt H.C., Hasskamp P., Schmedding I., Morandell S.,
RA   van Vugt M.A., Wang X., Linding R., Ong S.E., Weaver D., Carr S.A.,
RA   Yaffe M.B.;
RT   "DNA damage activates a spatially distinct late cytoplasmic cell-cycle
RT   checkpoint network controlled by MK2-mediated RNA stabilization.";
RL   Mol. Cell 40:34-49(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   SUMOYLATION AT LYS-353, AND MUTAGENESIS OF LYS-353.
RX   PubMed=21131586; DOI=10.1182/blood-2010-08-302281;
RA   Chang E., Heo K.S., Woo C.H., Lee H., Le N.T., Thomas T.N.,
RA   Fujiwara K., Abe J.;
RT   "MK2 SUMOylation regulates actin filament remodeling and subsequent
RT   migration in endothelial cells by inhibiting MK2 kinase and HSP27
RT   phosphorylation.";
RL   Blood 117:2527-2537(2011).
RN   [26]
RP   REVIEW.
RX   PubMed=18508601; DOI=10.2741/3095;
RA   Ronkina N., Kotlyarov A., Gaestel M.;
RT   "MK2 and MK3--a pair of isoenzymes?";
RL   Front. Biosci. 13:5511-5521(2008).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-334, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-334, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [29]
RP   FUNCTION.
RX   PubMed=26616734; DOI=10.1038/ncomms10075;
RA   Tollenaere M.A., Villumsen B.H., Blasius M., Nielsen J.C.,
RA   Wagner S.A., Bartek J., Beli P., Mailand N., Bekker-Jensen S.;
RT   "p38- and MK2-dependent signalling promotes stress-induced centriolar
RT   satellite remodelling via 14-3-3-dependent sequestration of
RT   CEP131/AZI1.";
RL   Nat. Commun. 6:10075-10075(2015).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) IN COMPLEX WITH ADP AND
RP   STAUROSPORINE, AND CATALYTIC ACTIVITY.
RX   PubMed=12171911; DOI=10.1074/jbc.C200418200;
RA   Meng W., Swenson L.L., Fitzgibbon M.J., Hayakawa K., Ter Haar E.,
RA   Behrens A.E., Fulghum J.R., Lippke J.A.;
RT   "Structure of mitogen-activated protein kinase-activated protein
RT   (MAPKAP) kinase 2 suggests a bifunctional switch that couples kinase
RT   activation with nuclear export.";
RL   J. Biol. Chem. 277:37401-37405(2002).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS).
RX   PubMed=12791252; DOI=10.1016/S0969-2126(03)00092-3;
RA   Underwood K.W., Parris K.D., Federico E., Mosyak L., Czerwinski R.M.,
RA   Shane T., Taylor M., Svenson K., Liu Y., Hsiao C.L., Wolfrom S.,
RA   Maguire M., Malakian K., Telliez J.B., Lin L.L., Kriz R.W., Seehra J.,
RA   Somers W.S., Stahl M.L.;
RT   "Catalytically active MAP KAP kinase 2 structures in complex with
RT   staurosporine and ADP reveal differences with the autoinhibited
RT   enzyme.";
RL   Structure 11:627-636(2003).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 41-364 IN COMPLEX WITH
RP   CARBOLINE-BASED INHIBITORS.
RX   PubMed=17576063; DOI=10.1016/j.bmcl.2007.05.101;
RA   Wu J.P., Wang J., Abeywardane A., Andersen D., Emmanuel M.,
RA   Gautschi E., Goldberg D.R., Kashem M.A., Lukas S., Mao W., Martin L.,
RA   Morwick T., Moss N., Pargellis C., Patel U.R., Patnaude L., Peet G.W.,
RA   Skow D., Snow R.J., Ward Y., Werneburg B., White A.;
RT   "The discovery of carboline analogs as potent MAPKAP-K2 inhibitors.";
RL   Bioorg. Med. Chem. Lett. 17:4664-4669(2007).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (4.0 ANGSTROMS) IN COMPLEX WITH MAPK14, AND
RP   INTERACTION WITH MAPK14.
RX   PubMed=17255097; DOI=10.1074/jbc.M611165200;
RA   ter Haar E., Prabhakar P., Liu X., Lepre C.;
RT   "Crystal structure of the p38 alpha-MAPKAP kinase 2 heterodimer.";
RL   J. Biol. Chem. 282:9733-9739(2007).
RN   [34]
RP   ERRATUM.
RA   ter Haar E., Prabhakar P., Liu X., Lepre C.;
RL   J. Biol. Chem. 282:14684-14684(2007).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (3.8 ANGSTROMS) OF 45-371 IN COMPLEX WITH
RP   PYRROLOPYRIDINE INHIBITORS.
RX   PubMed=17480064; DOI=10.1021/jm0611004;
RA   Anderson D.R., Meyers M.J., Vernier W.F., Mahoney M.W.,
RA   Kurumbail R.G., Caspers N., Poda G.I., Schindler J.F., Reitz D.B.,
RA   Mourey R.J.;
RT   "Pyrrolopyridine inhibitors of mitogen-activated protein kinase-
RT   activated protein kinase 2 (MK-2).";
RL   J. Med. Chem. 50:2647-2654(2007).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 41-364 IN COMPLEX WITH
RP   PYRROLOPYRIDINE INHIBITOR.
RX   PubMed=17449059; DOI=10.1016/j.jmb.2007.03.004;
RA   Hillig R.C., Eberspaecher U., Monteclaro F., Huber M., Nguyen D.,
RA   Mengel A., Muller-Tiemann B., Egner U.;
RT   "Structural basis for a high affinity inhibitor bound to protein
RT   kinase MK2.";
RL   J. Mol. Biol. 369:735-745(2007).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 47-400 IN COMPLEX WITH
RP   MAPK14, AND INTERACTION WITH MAPK14.
RX   PubMed=17395714; DOI=10.1073/pnas.0701679104;
RA   White A., Pargellis C.A., Studts J.M., Werneburg B.G., Farmer B.T. II;
RT   "Molecular basis of MAPK-activated protein kinase 2:p38 assembly.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:6353-6358(2007).
RN   [38]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLY-173 AND SER-361.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Stress-activated serine/threonine-protein kinase
CC       involved in cytokine production, endocytosis, reorganization of
CC       the cytoskeleton, cell migration, cell cycle control, chromatin
CC       remodeling, DNA damage response and transcriptional regulation.
CC       Following stress, it is phosphorylated and activated by MAP kinase
CC       p38-alpha/MAPK14, leading to phosphorylation of substrates.
CC       Phosphorylates serine in the peptide sequence, Hyd-X-R-X(2)-S,
CC       where Hyd is a large hydrophobic residue. Phosphorylates ALOX5,
CC       CDC25B, CDC25C, CEP131, ELAVL1, HNRNPA0, HSP27/HSPB1, KRT18,
CC       KRT20, LIMK1, LSP1, PABPC1, PARN, PDE4A, RCSD1, RPS6KA3, TAB3 and
CC       TTP/ZFP36. Phosphorylates HSF1; leading to the interaction with
CC       HSP90 proteins and inhibiting HSF1 homotrimerization, DNA-binding
CC       and transactivation activities (PubMed:16278218). Mediates
CC       phosphorylation of HSP27/HSPB1 in response to stress, leading to
CC       the dissociation of HSP27/HSPB1 from large small heat-shock
CC       protein (sHsps) oligomers and impairment of their chaperone
CC       activities and ability to protect against oxidative stress
CC       effectively. Involved in inflammatory response by regulating tumor
CC       necrosis factor (TNF) and IL6 production post-transcriptionally:
CC       acts by phosphorylating AU-rich elements (AREs)-binding proteins
CC       ELAVL1, HNRNPA0, PABPC1 and TTP/ZFP36, leading to the regulation
CC       of the stability and translation of TNF and IL6 mRNAs.
CC       Phosphorylation of TTP/ZFP36, a major post-transcriptional
CC       regulator of TNF, promotes its binding to 14-3-3 proteins and
CC       reduces its ARE mRNA affinity, leading to inhibition of dependent
CC       degradation of ARE-containing transcripts. Phosphorylates CEP131
CC       in response to cellular stress induced by ultraviolet irradiation
CC       which promotes binding of CEP131 to 14-3-3 proteins and inhibits
CC       formation of novel centriolar satellites (PubMed:26616734). Also
CC       involved in late G2/M checkpoint following DNA damage through a
CC       process of post-transcriptional mRNA stabilization: following DNA
CC       damage, relocalizes from nucleus to cytoplasm and phosphorylates
CC       HNRNPA0 and PARN, leading to stabilization of GADD45A mRNA.
CC       Involved in toll-like receptor signaling pathway (TLR) in
CC       dendritic cells: required for acute TLR-induced macropinocytosis
CC       by phosphorylating and activating RPS6KA3.
CC       {ECO:0000269|PubMed:10383393, ECO:0000269|PubMed:11844797,
CC       ECO:0000269|PubMed:12456657, ECO:0000269|PubMed:12565831,
CC       ECO:0000269|PubMed:14499342, ECO:0000269|PubMed:14517288,
CC       ECO:0000269|PubMed:15014438, ECO:0000269|PubMed:15629715,
CC       ECO:0000269|PubMed:16278218, ECO:0000269|PubMed:16456544,
CC       ECO:0000269|PubMed:17481585, ECO:0000269|PubMed:18021073,
CC       ECO:0000269|PubMed:20932473, ECO:0000269|PubMed:26616734,
CC       ECO:0000269|PubMed:8093612, ECO:0000269|PubMed:8280084,
CC       ECO:0000269|PubMed:8774846}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:12171911, ECO:0000269|PubMed:8774846}.
CC   -!- ENZYME REGULATION: Activated following phosphorylation by p38-
CC       alpha/MAPK14 following various stresses. Inhibited following
CC       sumoylation. Specifically inhibited by pyrrolopyridine inhibitors.
CC   -!- SUBUNIT: Heterodimer with p38-alpha/MAPK14; this heterodimer forms
CC       a stable complex: molecules are positioned 'face to face' so that
CC       the ATP-binding sites of both kinases are at the heterodimer
CC       interface (PubMed:12171911, PubMed:17576063, PubMed:17255097,
CC       PubMed:17480064, PubMed:17449059, PubMed:17395714). Interacts with
CC       PHC2 (PubMed:15094067). Interacts with HSF1 (PubMed:16278218).
CC       {ECO:0000269|PubMed:12171911, ECO:0000269|PubMed:15094067,
CC       ECO:0000269|PubMed:16278218, ECO:0000269|PubMed:17255097,
CC       ECO:0000269|PubMed:17395714, ECO:0000269|PubMed:17449059,
CC       ECO:0000269|PubMed:17480064, ECO:0000269|PubMed:17576063}.
CC   -!- INTERACTION:
CC       Q00613:HSF1; NbExp=5; IntAct=EBI-993299, EBI-719620;
CC       P04792:HSPB1; NbExp=3; IntAct=EBI-993299, EBI-352682;
CC       Q16539:MAPK14; NbExp=7; IntAct=EBI-993299, EBI-73946;
CC       Q9QWH1:Phc2 (xeno); NbExp=2; IntAct=EBI-993299, EBI-642357;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:20932473}.
CC       Nucleus {ECO:0000269|PubMed:20932473}. Note=Phosphorylation and
CC       subsequent activation releases the autoinhibitory helix, resulting
CC       in the export from the nucleus into the cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P49137-1; Sequence=Displayed;
CC         Note=Has a nuclear localization signal.;
CC       Name=2;
CC         IsoId=P49137-2; Sequence=VSP_004910;
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues examined.
CC   -!- PTM: Sumoylation inhibits the protein kinase activity.
CC       {ECO:0000269|PubMed:21131586}.
CC   -!- PTM: Phosphorylated and activated by MAP kinase p38-alpha/MAPK14
CC       at Thr-222, Ser-272 and Thr-334. {ECO:0000269|PubMed:8846784}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MAPKAPK2ID41295ch1q32.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U12779; AAA20851.1; -; mRNA.
DR   EMBL; AL591846; CAI13543.1; -; Genomic_DNA.
DR   EMBL; AL591846; CAI13544.1; -; Genomic_DNA.
DR   EMBL; CH471100; EAW93526.1; -; Genomic_DNA.
DR   EMBL; CH471100; EAW93529.1; -; Genomic_DNA.
DR   EMBL; BC036060; AAH36060.2; -; mRNA.
DR   EMBL; BC052584; AAH52584.1; -; mRNA.
DR   EMBL; X75346; CAA53094.1; -; mRNA.
DR   CCDS; CCDS1466.1; -. [P49137-2]
DR   CCDS; CCDS31001.1; -. [P49137-1]
DR   PIR; JC2204; JC2204.
DR   PIR; S39793; S39793.
DR   RefSeq; NP_004750.1; NM_004759.4. [P49137-2]
DR   RefSeq; NP_116584.2; NM_032960.3. [P49137-1]
DR   UniGene; Hs.643566; -.
DR   UniGene; Hs.713747; -.
DR   PDB; 1KWP; X-ray; 2.80 A; A/B=1-400.
DR   PDB; 1NXK; X-ray; 2.70 A; A/B/C/D=1-400.
DR   PDB; 1NY3; X-ray; 3.00 A; A=1-400.
DR   PDB; 2JBO; X-ray; 3.10 A; A=41-364.
DR   PDB; 2JBP; X-ray; 3.31 A; A/B/C/D/E/F/G/H/I/J/K/L=41-364.
DR   PDB; 2OKR; X-ray; 2.00 A; C/F=370-393.
DR   PDB; 2ONL; X-ray; 4.00 A; C/D=1-400.
DR   PDB; 2OZA; X-ray; 2.70 A; A=47-400.
DR   PDB; 2P3G; X-ray; 3.80 A; X=45-371.
DR   PDB; 2PZY; X-ray; 2.90 A; A/B/C/D=41-364.
DR   PDB; 3A2C; X-ray; 2.90 A; A/B/C/D/E/F/G/H/I/J/K/L=41-364.
DR   PDB; 3FPM; X-ray; 3.30 A; A=41-364.
DR   PDB; 3FYJ; X-ray; 3.80 A; X=45-371.
DR   PDB; 3FYK; X-ray; 3.50 A; X=45-371.
DR   PDB; 3GOK; X-ray; 3.20 A; A/B/C/D/E/F/G/H/I/J/K/L=41-364.
DR   PDB; 3KA0; X-ray; 2.90 A; A=47-366.
DR   PDB; 3KC3; X-ray; 2.90 A; A/B/C/D/E/F/G/H/I/J/K/L=41-364.
DR   PDB; 3KGA; X-ray; 2.55 A; A=47-364.
DR   PDB; 3M2W; X-ray; 2.41 A; A=47-364.
DR   PDB; 3M42; X-ray; 2.68 A; A=47-364.
DR   PDB; 3R2B; X-ray; 2.90 A; A/B/C/D/E/F/G/H/I/J/K/L=47-364.
DR   PDB; 3R2Y; X-ray; 3.00 A; A=46-364.
DR   PDB; 3R30; X-ray; 3.20 A; A=46-364.
DR   PDB; 3WI6; X-ray; 2.99 A; A/B/C/D/E/F=41-364.
DR   PDB; 4TYH; X-ray; 3.00 A; A=51-400.
DR   PDBsum; 1KWP; -.
DR   PDBsum; 1NXK; -.
DR   PDBsum; 1NY3; -.
DR   PDBsum; 2JBO; -.
DR   PDBsum; 2JBP; -.
DR   PDBsum; 2OKR; -.
DR   PDBsum; 2ONL; -.
DR   PDBsum; 2OZA; -.
DR   PDBsum; 2P3G; -.
DR   PDBsum; 2PZY; -.
DR   PDBsum; 3A2C; -.
DR   PDBsum; 3FPM; -.
DR   PDBsum; 3FYJ; -.
DR   PDBsum; 3FYK; -.
DR   PDBsum; 3GOK; -.
DR   PDBsum; 3KA0; -.
DR   PDBsum; 3KC3; -.
DR   PDBsum; 3KGA; -.
DR   PDBsum; 3M2W; -.
DR   PDBsum; 3M42; -.
DR   PDBsum; 3R2B; -.
DR   PDBsum; 3R2Y; -.
DR   PDBsum; 3R30; -.
DR   PDBsum; 3WI6; -.
DR   PDBsum; 4TYH; -.
DR   ProteinModelPortal; P49137; -.
DR   SMR; P49137; -.
DR   BioGrid; 114683; 53.
DR   DIP; DIP-35671N; -.
DR   IntAct; P49137; 14.
DR   MINT; MINT-1539725; -.
DR   STRING; 9606.ENSP00000356070; -.
DR   BindingDB; P49137; -.
DR   ChEMBL; CHEMBL2208; -.
DR   DrugBank; DB02010; Staurosporine.
DR   GuidetoPHARMACOLOGY; 2094; -.
DR   iPTMnet; P49137; -.
DR   PhosphoSitePlus; P49137; -.
DR   BioMuta; MAPKAPK2; -.
DR   DMDM; 1346538; -.
DR   EPD; P49137; -.
DR   MaxQB; P49137; -.
DR   PaxDb; P49137; -.
DR   PeptideAtlas; P49137; -.
DR   PRIDE; P49137; -.
DR   DNASU; 9261; -.
DR   Ensembl; ENST00000294981; ENSP00000294981; ENSG00000162889. [P49137-2]
DR   Ensembl; ENST00000367103; ENSP00000356070; ENSG00000162889. [P49137-1]
DR   GeneID; 9261; -.
DR   KEGG; hsa:9261; -.
DR   UCSC; uc001hel.3; human. [P49137-1]
DR   CTD; 9261; -.
DR   DisGeNET; 9261; -.
DR   GeneCards; MAPKAPK2; -.
DR   HGNC; HGNC:6887; MAPKAPK2.
DR   HPA; CAB010297; -.
DR   HPA; HPA045556; -.
DR   HPA; HPA063708; -.
DR   HPA; HPA064435; -.
DR   MIM; 602006; gene.
DR   neXtProt; NX_P49137; -.
DR   OpenTargets; ENSG00000162889; -.
DR   PharmGKB; PA30631; -.
DR   eggNOG; KOG0604; Eukaryota.
DR   eggNOG; ENOG410XP8F; LUCA.
DR   GeneTree; ENSGT00830000128274; -.
DR   HOGENOM; HOG000233031; -.
DR   HOVERGEN; HBG106948; -.
DR   InParanoid; P49137; -.
DR   KO; K04443; -.
DR   OMA; LQMLQDC; -.
DR   OrthoDB; EOG091G14PL; -.
DR   PhylomeDB; P49137; -.
DR   TreeFam; TF312891; -.
DR   BioCyc; MetaCyc:HS08751-MONOMER; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; R-HSA-171007; p38MAPK events.
DR   Reactome; R-HSA-199920; CREB phosphorylation.
DR   Reactome; R-HSA-2142691; Synthesis of Leukotrienes (LT) and Eoxins (EX).
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-3371453; Regulation of HSF1-mediated heat shock response.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-450302; activated TAK1 mediates p38 MAPK activation.
DR   Reactome; R-HSA-450385; Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA.
DR   Reactome; R-HSA-450513; Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA.
DR   SignaLink; P49137; -.
DR   SIGNOR; P49137; -.
DR   ChiTaRS; MAPKAPK2; human.
DR   EvolutionaryTrace; P49137; -.
DR   GeneWiki; MAPKAPK2; -.
DR   GenomeRNAi; 9261; -.
DR   PRO; PR:P49137; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000162889; -.
DR   CleanEx; HS_MAPKAPK2; -.
DR   Genevisible; P49137; HS.
DR   GO; GO:0005813; C:centrosome; IDA:HPA.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0009931; F:calcium-dependent protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0005516; F:calmodulin binding; IBA:GO_Central.
DR   GO; GO:0004683; F:calmodulin-dependent protein kinase activity; IBA:GO_Central.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004871; F:signal transducer activity; TAS:ProtInc.
DR   GO; GO:0070935; P:3'-UTR-mediated mRNA stabilization; IDA:UniProtKB.
DR   GO; GO:0000187; P:activation of MAPK activity; TAS:Reactome.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IMP:UniProtKB.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IMP:BHF-UCL.
DR   GO; GO:0031572; P:G2 DNA damage checkpoint; IMP:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; ISS:UniProtKB.
DR   GO; GO:0048839; P:inner ear development; IEA:Ensembl.
DR   GO; GO:0006691; P:leukotriene metabolic process; TAS:Reactome.
DR   GO; GO:0044351; P:macropinocytosis; ISS:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; TAS:ProtInc.
DR   GO; GO:0038066; P:p38MAPK cascade; IEA:Ensembl.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0042535; P:positive regulation of tumor necrosis factor biosynthetic process; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IBA:GO_Central.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.
DR   GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome.
DR   GO; GO:0032675; P:regulation of interleukin-6 production; ISS:UniProtKB.
DR   GO; GO:0043488; P:regulation of mRNA stability; TAS:Reactome.
DR   GO; GO:0032680; P:regulation of tumor necrosis factor production; IDA:UniProtKB.
DR   GO; GO:0034097; P:response to cytokine; IDA:UniProtKB.
DR   GO; GO:0032496; P:response to lipopolysaccharide; ISS:UniProtKB.
DR   GO; GO:0006950; P:response to stress; IDA:UniProtKB.
DR   GO; GO:0002224; P:toll-like receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IMP:BHF-UCL.
DR   Gene3D; 4.10.1170.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR027442; MAPKAPK_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Cytoplasm; DNA damage; Isopeptide bond; Kinase; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN         1    400       MAP kinase-activated protein kinase 2.
FT                                /FTId=PRO_0000086288.
FT   DOMAIN       64    325       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      70     78       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      139    141       Staurosporine binding.
FT   REGION      328    364       Autoinhibitory helix. {ECO:0000250}.
FT   REGION      366    390       p38 MAPK-binding site.
FT   MOTIF       356    365       Nuclear export signal (NES).
FT   MOTIF       371    374       Bipartite nuclear localization signal 1.
FT   MOTIF       385    389       Bipartite nuclear localization signal 2.
FT   COMPBIAS     10     40       Pro-rich.
FT   COMPBIAS     35     40       Poly-Pro.
FT   ACT_SITE    186    186       Proton acceptor.
FT   BINDING      93     93       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       9      9       Phosphoserine.
FT                                {ECO:0000269|PubMed:8846784}.
FT   MOD_RES      25     25       Phosphothreonine.
FT                                {ECO:0000269|PubMed:8846784}.
FT   MOD_RES     222    222       Phosphothreonine; by MAPK14.
FT                                {ECO:0000269|PubMed:8846784}.
FT   MOD_RES     272    272       Phosphoserine; by MAPK14.
FT                                {ECO:0000269|PubMed:8846784}.
FT   MOD_RES     328    328       Phosphoserine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     334    334       Phosphothreonine; by MAPK14.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:8846784}.
FT   CROSSLNK    353    353       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000269|PubMed:21131586}.
FT   VAR_SEQ     354    400       EEMTSALATMRVDYEQIKIKKIEDASNPLLLKRRKKARALE
FT                                AAALAH -> GCLHDKNSDQATWLTRL (in isoform
FT                                2). {ECO:0000303|PubMed:8179591}.
FT                                /FTId=VSP_004910.
FT   VARIANT     173    173       A -> G (in dbSNP:rs35671930).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040753.
FT   VARIANT     361    361       A -> S (in dbSNP:rs55894011).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040754.
FT   MUTAGEN      93     93       K->R: Kinase defective mutant, abolishes
FT                                activity. {ECO:0000269|PubMed:14517288}.
FT   MUTAGEN     207    207       D->A: Kinase defective mutant, abolishes
FT                                activity. {ECO:0000269|PubMed:8846784}.
FT   MUTAGEN     222    222       T->A: Strong decrease in kinase activity.
FT                                {ECO:0000269|PubMed:14517288,
FT                                ECO:0000269|PubMed:15014438,
FT                                ECO:0000269|PubMed:8846784}.
FT   MUTAGEN     222    222       T->D: Mimicks phosphorylation state,
FT                                leading to slight increase of basal
FT                                kinase activity.
FT                                {ECO:0000269|PubMed:14517288,
FT                                ECO:0000269|PubMed:15014438,
FT                                ECO:0000269|PubMed:8846784}.
FT   MUTAGEN     222    222       T->E: Mimicks phosphorylation state and
FT                                constitutive protein kinase activity;
FT                                when associated with E-334.
FT                                {ECO:0000269|PubMed:14517288,
FT                                ECO:0000269|PubMed:15014438,
FT                                ECO:0000269|PubMed:8846784}.
FT   MUTAGEN     272    272       S->A: Strong decrease in kinase activity.
FT                                {ECO:0000269|PubMed:8846784}.
FT   MUTAGEN     272    272       S->D: Mimicks phosphorylation state,
FT                                leading to slight increase of basal
FT                                kinase activity.
FT                                {ECO:0000269|PubMed:8846784}.
FT   MUTAGEN     334    334       T->A: Slight decrease in kinase activity.
FT                                {ECO:0000269|PubMed:14517288,
FT                                ECO:0000269|PubMed:15014438,
FT                                ECO:0000269|PubMed:8846784}.
FT   MUTAGEN     334    334       T->D,E: Mimicks phosphorylation state,
FT                                leading to elevated basal kinase
FT                                activity. {ECO:0000269|PubMed:14517288,
FT                                ECO:0000269|PubMed:15014438,
FT                                ECO:0000269|PubMed:8846784}.
FT   MUTAGEN     334    334       T->E: Mimicks phosphorylation state and
FT                                constitutive protein kinase activity;
FT                                when associated with E-222.
FT                                {ECO:0000269|PubMed:14517288,
FT                                ECO:0000269|PubMed:15014438,
FT                                ECO:0000269|PubMed:8846784}.
FT   MUTAGEN     353    353       K->R: Induces decreased sumoylation and
FT                                increase in protein kinase activity.
FT                                {ECO:0000269|PubMed:21131586}.
FT   CONFLICT    116    116       H -> D (in Ref. 5; CAA53094).
FT                                {ECO:0000305}.
FT   CONFLICT    247    248       WS -> LV (in Ref. 5; CAA53094).
FT                                {ECO:0000305}.
FT   HELIX        45     47       {ECO:0000244|PDB:1NXK}.
FT   STRAND       48     50       {ECO:0000244|PDB:1NXK}.
FT   HELIX        59     61       {ECO:0000244|PDB:3M2W}.
FT   STRAND       63     73       {ECO:0000244|PDB:3M2W}.
FT   STRAND       76     83       {ECO:0000244|PDB:3M2W}.
FT   TURN         84     86       {ECO:0000244|PDB:3M2W}.
FT   STRAND       89     96       {ECO:0000244|PDB:3M2W}.
FT   HELIX        99    111       {ECO:0000244|PDB:3M2W}.
FT   STRAND      114    117       {ECO:0000244|PDB:3FYK}.
FT   STRAND      120    128       {ECO:0000244|PDB:3M2W}.
FT   STRAND      131    138       {ECO:0000244|PDB:3M2W}.
FT   STRAND      143    145       {ECO:0000244|PDB:1NXK}.
FT   HELIX       146    152       {ECO:0000244|PDB:3M2W}.
FT   HELIX       160    179       {ECO:0000244|PDB:3M2W}.
FT   HELIX       189    191       {ECO:0000244|PDB:3M2W}.
FT   STRAND      192    198       {ECO:0000244|PDB:3M2W}.
FT   STRAND      203    205       {ECO:0000244|PDB:3M2W}.
FT   STRAND      212    214       {ECO:0000244|PDB:3WI6}.
FT   STRAND      228    230       {ECO:0000244|PDB:3FPM}.
FT   HELIX       232    234       {ECO:0000244|PDB:1NXK}.
FT   HELIX       239    242       {ECO:0000244|PDB:3M2W}.
FT   HELIX       243    258       {ECO:0000244|PDB:3M2W}.
FT   STRAND      264    266       {ECO:0000244|PDB:4TYH}.
FT   STRAND      267    269       {ECO:0000244|PDB:1KWP}.
FT   HELIX       275    281       {ECO:0000244|PDB:1NXK}.
FT   STRAND      283    285       {ECO:0000244|PDB:2OZA}.
FT   HELIX       288    291       {ECO:0000244|PDB:3M2W}.
FT   HELIX       296    305       {ECO:0000244|PDB:3M2W}.
FT   TURN        310    312       {ECO:0000244|PDB:3M2W}.
FT   HELIX       316    320       {ECO:0000244|PDB:3M2W}.
FT   HELIX       323    326       {ECO:0000244|PDB:3M2W}.
FT   HELIX       328    330       {ECO:0000244|PDB:3M2W}.
FT   STRAND      335    337       {ECO:0000244|PDB:3M42}.
FT   HELIX       338    344       {ECO:0000244|PDB:3M2W}.
FT   HELIX       346    348       {ECO:0000244|PDB:3M2W}.
FT   HELIX       349    363       {ECO:0000244|PDB:3M2W}.
FT   TURN        375    377       {ECO:0000244|PDB:2OKR}.
FT   HELIX       381    389       {ECO:0000244|PDB:2OKR}.
SQ   SEQUENCE   400 AA;  45568 MW;  E4EFFF11CCF288DC CRC64;
     MLSNSQGQSP PVPFPAPAPP PQPPTPALPH PPAQPPPPPP QQFPQFHVKS GLQIKKNAII
     DDYKVTSQVL GLGINGKVLQ IFNKRTQEKF ALKMLQDCPK ARREVELHWR ASQCPHIVRI
     VDVYENLYAG RKCLLIVMEC LDGGELFSRI QDRGDQAFTE REASEIMKSI GEAIQYLHSI
     NIAHRDVKPE NLLYTSKRPN AILKLTDFGF AKETTSHNSL TTPCYTPYYV APEVLGPEKY
     DKSCDMWSLG VIMYILLCGY PPFYSNHGLA ISPGMKTRIR MGQYEFPNPE WSEVSEEVKM
     LIRNLLKTEP TQRMTITEFM NHPWIMQSTK VPQTPLHTSR VLKEDKERWE DVKEEMTSAL
     ATMRVDYEQI KIKKIEDASN PLLLKRRKKA RALEAAALAH
//
